BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
BioVaxys Reports Positive Phase 2 Data for Maveropepimut + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
QIMC Completes 711 Metre Discovery Hole DDH-26-01 at West-Advocate, Nova Scotia: Hydrogen System Confirmed at Depth
CORRECTION FROM SOURCE: Allied Critical Metals Further Highlights Rapid Payback, Capital Efficiency and Infrastructure from Borralha PEA
Homerun Resources Inc. and UC Davis Produce Fused Silica Glass from SME Silica Sand Using Fast Joule Heating and File Patent Application for Femtosecond Silica Purification Process
